| The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. | |
| | |
MedLine Citation:
|
PMID: 20709060 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated Bax activation and cell apoptosis. However, this report demonstrates that SP600125 synergistically enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation. The dynamical analysis of GFP-Bax mobility inside single living cells using fluorescence recovery after photobleaching revealed that SP600125 aggravated the DHA-induced decrease of Bax mobility and Bax translocation. These results for the first time present a novel pro-apoptotic action of SP600125 in DHA-induced apoptosis. |
| | |
Authors:
|
Ying-Ying Lu; Tong-Sheng Chen; Xiao-Ping Wang; Jun-Le Qu; Min Chen |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-13 |
Journal Detail:
|
Title: FEBS letters Volume: 584 ISSN: 1873-3468 ISO Abbreviation: FEBS Lett. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2010-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0155157 Medline TA: FEBS Lett Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 4019-26 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, South China Normal University, Guangzhou, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anthracenes
/
pharmacology* Apoptosis / drug effects* Artemisinins / pharmacology Cell Line, Tumor Humans JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors* Mitochondria / metabolism* Protein Kinase Inhibitors / pharmacology* Protein Transport / drug effects bcl-2-Associated X Protein / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Anthracenes; 0/Artemisinins; 0/Protein Kinase Inhibitors; 0/anthra(1,9-cd)pyrazol-6(2H)-one; 0/bcl-2-Associated X Protein; 71939-50-9/dihydroquinghaosu; EC 2.7.11.24/JNK Mitogen-Activated Protein Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sodium channel mutations and epilepsy: association and causation.
Next Document: Structural implications for K5/K12-di-acetylated histone H4 recognition by the second bromodomain of...